Eli Lilly is introducing two lower-price insulins in the US following earlier efforts and encouragement from policymakers.
Its new lower-priced insulins will have 50% lower list prices compared to the branded versions. Both will be available in mid-April, the company said.
With these new options, more than 90% of people using a Humalog formulation will have access to a lower-priced version that may reduce their out-of-pocket costs, the company said.
This follows the company’s earlier efforts to launch lower-priced insulins to market. In May 2019, the company launched Insulin Lispro at a 50% lower list price.
Today, Lispro can be ordered at any US pharmacy. The company said it has “started negotiations” with wholesalers and payers to make these two new lower-priced insulins available too.